EULAR 2012 Investor Science Call

Roche conference call for investors and analysts from EULAR 2012

ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab.

The conference call took place on:Friday, 8 June 2012

Investor Updates

  • Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy read more
  • Roche conference call for investors and analysts from EULAR 2012 read more

Webcast